WWM
EDIT icon

Willingdon Wealth Management’s Editas Medicine EDIT Stock Holding History

Willingdon Wealth Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-9
Closed – – 419
2019
Q3 		$0 Buy
+9
New +$223 ﹤0.01% 511

Other funds holding EDIT

NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Willingdon Wealth Management's EDIT Position: Q4 2019 in Review

Willingdon Wealth Management sold out of Editas Medicine (EDIT) in Q4 2019, closing a stake of 9 shares.

Willingdon Wealth Management first reported a position in EDIT in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 229 funds tracked by Wall St. Rank hold EDIT as of Q4 2019.

  • Willingdon Wealth Management reported no remaining Editas Medicine position as of Q4 2019 after selling out during the quarter.
  • Willingdon Wealth Management sold 9 Editas Medicine shares in Q4 2019.
  • Willingdon Wealth Management first reported a position in Editas Medicine in Q3 2019 and held it in 1 quarter.
  • Willingdon Wealth Management's Editas Medicine position peaked at $0 in Q3 2019.
  • 229 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2019.

Based on Willingdon Wealth Management's 13F filing for Q4 2019, filed 10 Feb 2020.